Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of PXL-01 for Prevention of Postsurgical Adhesions after Tendon and Nerve Repairs in the Hand

Trial Profile

A Phase III Study of PXL-01 for Prevention of Postsurgical Adhesions after Tendon and Nerve Repairs in the Hand

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensereptide (Primary)
  • Indications Post-surgical adhesions
  • Focus Registrational; Therapeutic Use
  • Sponsors ProMore Pharma
  • Most Recent Events

    • 01 Feb 2019 According to a ProMore Pharma media release, the company is working towards the goal of being able to start our clinical study no later than the first half of 2020.
    • 01 Feb 2019 According to a ProMore Pharma media release, due to number of manufacturing issues of investigational drug the company is fixing the manufacturing chain. The company plans to increase number of clinics (including hospitals in Italy) to reduce the likelihood of time loss.
    • 19 Nov 2018 According to a ProMore Pharma media release, the company has received approval from the Drug Controller General of India to initiate this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top